7th April 2017

REQUEST FOR PROPOSAL DUE TO MARKET AND COST RESEARCH

THE GOAL OF THIS REQUEST IS TO DISSEMINATE INFORMATION ABOUT PLANNED PUBLIC PROCUREMENT AND TO COLLECT COST OFFERS.

In connection with obtaining the decision of granting the project No. STRATEGMED2/265566/6/NCBR/ entitled: "Preclinical and clinical develoment of a new TRAIL-derived biomolecule, triggering multiple cell death pathways for therapy of cancer - comprehensive research network for early phase oncology clinical trials in Poland" under STRATEGMED Programme, acting on the basis of §7 section 4 of the grant agreement, a beneficiary Maria Sklodowska- Curie Cancer Memorial Center invites those who are interested to submit cost offers for the public procurement.

Subject of the public procurement:

Toxicology studies on the biologic, anticancer molecule AD-O-51.4. Measurement of pharmacokinetics parameters and assessment of safety pharmacology of AD-O-51 in living organisms. Performing a IND/CTA-enabling package of non-clinical toxicology and safety pharmacology studies in compliance with International Conference on Harmonisation (ICH), European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines.

The required public procurement includes the following elements:

a. Development of a detailed plan of non-clinical IND/CTA-enabling studies adjusted to properties and therapeutic indications of AD-O-51.4.
b. Performing a non-GLP, single dose, dose-escalation study for AD-O-51.4 to determine the Maximum Tolerated Dose (MTD) in rats (Rattus norvegicus) and cynomolgus monkeys (Macaca fascicularis). Study plan should be proposed by the Tenderer according to the Section 1 in Appendix 3 to the offer (Study Plan).
c. Performing a non-GLP, repeated dose Dose Range Finding (DRF) toxicology study to determine the MTD of AD-O-51.4. Intravenous administration by infusion to rats and cynomolgus monkeys. Study plan should be proposed by the Tenderer according to the Section 2 in Appendix 3 to the offer (Study Plan).
d. 28-day repeated-dose OECD GLP toxicology study in rats with 14-day recovery period. Study performed in compliance with EMA/FDA guidelines, in particular: ICH M3(R2), ICH S6, ICH S9 and CPMP/SWP/1042/99 Rev 1 Corr. In this study, measurements of the AD-O-51.4 concentration in the rat plasma should be performed using LC-MS/MS method.
e. 28-day repeated-dose OECD GLP toxicology study in cynomolgus monkeys with 14-day recovery period. Study performed in compliance with EMA/FDA guidelines, in particular: ICH M3(R2), ICH S6, ICH S9 and CPMP/SWP/1042/99 Rev 1 Corr. In this study, measurements of

the AD-O-51.4 concentration in the rat plasma should be performed using LC-MS/MS method.

f. Histopathological analyses, pharmacokinetic, toxokinetics and toxicology data analyses and interpretation of results of beforementioned studies.
g. Preparation of a final report covering all studies (GLP and Non-GLP studies) in eCTD format.
h. Development and validation of High Performance Liquid Chromatography (HPLC) method to measure the concentration of AD-O-51.4 in the GLP standard.
i. Development and validation of liquid chromatography–mass spectrometry (LC-MS/MS) method to measure the concentration of AD-O-51.4 in human, rat and cynomolgus monkeys in the OECD GLP standard.
j. Development and validation of method for the detection of anti- AD-O-51.4 in animal plasma, according to OECD GLP.
k. Detection of the anti- AD-O-51.4 antibodies in the rat and cynomolgus monkeys according to GLP/OECD.

The public procurement is planned to be performed in 3rd and 4th period of 2017.

The date and the way of submission:

1. The deadline for the submission is April 18 2017, 12.00 PM.
2. The offer is to be sent in writing to: Osrodek Badan Wczesnych Faz, Centrum Onkologii- Instytut im. Marii Sklodowskiej- Curie w Warszawie, ul. Roentgena 5 02-781 Warszawa, or as an email to: janowskaa@coi.pl

Additional information:

Any questions related to the subject matter of this request should be directed to the address: janowskaa@coi.pl